Darunavir

"Darunavir" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

An HIV PROTEASE INHIBITOR that is used in the treatment of AIDS and HIV INFECTIONS. Due to the emergence of ANTIVIRAL DRUG RESISTANCE when used alone, it is administered in combination with other ANTI-HIV AGENTS.

Descriptor ID	D000069454
MeSH Number(s)	D02.065.884.438 D02.241.081.251.222 D02.886.590.700.400 D03.383.312.303
Concept/Terms	Darunavir Darunavir Prezista Prezista UIC-94017 UIC-94017 UIC 94017 UIC94017 Darunavir Ethanolate Darunavir Ethanolate Ethanolate, Darunavir TMC 114 TMC 114 114, TMC TMC114 TMC-114

Below are MeSH descriptors whose meaning is more general than "Darunavir".

Chemicals and Drugs [D]
Organic Chemicals [D02]
Amides [D02.065]
Sulfonamides [D02.065.884]
Darunavir [D02.065.884.438]
Carboxylic Acids [D02.241]
Acids, Acyclic [D02.241.081]
Carbamates [D02.241.081.251]
Darunavir [D02.241.081.251.222]
Sulfur Compounds [D02.886]
Sulfones [D02.886.590]
Sulfonamides [D02.886.590.700]
Darunavir [D02.886.590.700.400]
Heterocyclic Compounds [D03]
Heterocyclic Compounds, 1-Ring [D03.383]
Furans [D03.383.312]
Darunavir [D03.383.312.303]

Below are MeSH descriptors whose meaning is more specific than "Darunavir".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Darunavir" by people in this website by year, and whether "Darunavir" was a major or minor topic of these publications.

Bar chart showing 16 publications over 14 distinct years, with a maximum of 2 publications in 2008 and 2023

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2004	0	1	1
2005	0	1	1
2008	0	2	2
2010	0	1	1
2011	0	1	1
2012	0	1	1
2013	0	1	1
2014	0	1	1
2017	1	0	1
2018	1	0	1
2019	1	0	1
2020	0	1	1
2021	1	0	1
2023	0	2	2

Below are the most recent publications written about "Darunavir" by people in Profiles.

Lockbaum GJ, Rusere LN, Henes M, Kosovrasti K, Rao DN, Spielvogel E, Lee SK, Nalivaika EA, Swanstrom R, Yilmaz NK, Schiffer CA, Ali A. HIV-1 protease inhibitors with a P1 phosphonate modification maintain potency against drug-resistant variants by increased interactions with flap residues. Eur J Med Chem. 2023 Sep 05; 257:115501.

View in: PubMed
Spielvogel E, Lee SK, Zhou S, Lockbaum GJ, Henes M, Sondgeroth A, Kosovrasti K, Nalivaika EA, Ali A, Yilmaz NK, Schiffer CA, Swanstrom R. Selection of HIV-1 for resistance to fifth-generation protease inhibitors reveals two independent pathways to high-level resistance. Elife. 2023 03 15; 12.

View in: PubMed
Lockbaum GJ, Henes M, Talledge N, Rusere LN, Kosovrasti K, Nalivaika EA, Somasundaran M, Ali A, Mansky LM, Kurt Yilmaz N, Schiffer CA. Inhibiting HTLV-1 Protease: A Viable Antiviral Target. ACS Chem Biol. 2021 03 19; 16(3):529-538.

View in: PubMed
Rusere LN, Lockbaum GJ, Henes M, Lee SK, Spielvogel E, Rao DN, Kosovrasti K, Nalivaika EA, Swanstrom R, Kurt Yilmaz N, Schiffer CA, Ali A. Structural Analysis of Potent Hybrid HIV-1 Protease Inhibitors Containing Bis-tetrahydrofuran in a Pseudosymmetric Dipeptide Isostere. J Med Chem. 2020 08 13; 63(15):8296-8313.

View in: PubMed
Henes M, Lockbaum GJ, Kosovrasti K, Leidner F, Nachum GS, Nalivaika EA, Lee SK, Spielvogel E, Zhou S, Swanstrom R, Bolon DNA, Kurt Yilmaz N, Schiffer CA. Picomolar to Micromolar: Elucidating the Role of Distal Mutations in HIV-1 Protease in Conferring Drug Resistance. ACS Chem Biol. 2019 11 15; 14(11):2441-2452.

View in: PubMed
Lockbaum GJ, Leidner F, Rusere LN, Henes M, Kosovrasti K, Nachum GS, Nalivaika EA, Ali A, Yilmaz NK, Schiffer CA. Structural Adaptation of Darunavir Analogues against Primary Mutations in HIV-1 Protease. ACS Infect Dis. 2019 02 08; 5(2):316-325.

View in: PubMed
Paulsen JL, Leidner F, Ragland DA, Kurt Yilmaz N, Schiffer CA. Interdependence of Inhibitor Recognition in HIV-1 Protease. J Chem Theory Comput. 2017 May 09; 13(5):2300-2309.

View in: PubMed
Ragland DA, Nalivaika EA, Nalam MN, Prachanronarong KL, Cao H, Bandaranayake RM, Cai Y, Kurt-Yilmaz N, Schiffer CA. Drug resistance conferred by mutations outside the active site through alterations in the dynamic and structural ensemble of HIV-1 protease. J Am Chem Soc. 2014 Aug 27; 136(34):11956-63.

View in: PubMed
Mittal S, Bandaranayake RM, King NM, Prabu-Jeyabalan M, Nalam MN, Nalivaika EA, Yilmaz NK, Schiffer CA. Structural and thermodynamic basis of amprenavir/darunavir and atazanavir resistance in HIV-1 protease with mutations at residue 50. J Virol. 2013 Apr; 87(8):4176-84.

View in: PubMed
Davis DA, Soule EE, Davidoff KS, Daniels SI, Naiman NE, Yarchoan R. Activity of human immunodeficiency virus type 1 protease inhibitors against the initial autocleavage in Gag-Pol polyprotein processing. Antimicrob Agents Chemother. 2012 Jul; 56(7):3620-8.

View in: PubMed

People

Explore

Similar Concepts

Top Journals